Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to
your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
› More search options
Prof Michael Baum
The Clinical Trials Group, Dept.of Surgery
Clerkenwell Bldg, Whittington Campus
London
N19 5LW
Appointment
- Emeritus Professor of Surgery
- Department of Surgical Biotechnology
- Div of Surgery & Interventional Sci
- Faculty of Medical Sciences
Research Themes
See More
See LessResearch Summary
* I established the first multi-centre collaborative group for trials of treatment for breast cancer in 1970 and on the back of that the first purpose built clinical trials centre in 1980.
* I established the first nurse counselling service at Kings College Hospital in 1981 and the first psychosocial oncology research team at the same time.
* I developed the first psychometric instrument for measuring quality of life in patients undergoing treatment for cancer (LASA).
* My group were also involved in developing the ethical models for randomised controlled trials and the development of informed consent procedures. This also included a consumer's advisory group. As Vice President of EUSOMA I was in part instrumental in building up EUROPA DONNA and worked closely with this organization as President of the third European Breast Cancer Conference 2002 in Barcelona that lead to the Statement of Barcelona on behalf of EUSOMA, EORTC and EUROPA DONNA.
* My group was the first to show the survival advantage of adjuvant tamoxifen, which has contributed to the 30% fall in breast cancer mortality over the last 15 years.
* As a spin off from these trials we were also the first to note the potential of tamoxifen to prevent breast cancer.
* Most recently I have put together the biggest International cancer trials group in history (ATAC), which in record time demonstrated the superiority of Anastrozole to tamoxifen. Anastrozole was endorsed by NICE as the preferred treatment for hormone responsive postmenopausal women with breast cancer in June 2006.
* Alongside this trial of over 9,000 patients we have a subcommittee responsible for collecting and storing archival material for translational research that will relate the response of the aromatase inhibitors to various phenotypes of breast cancer based on steroid and growth factor receptors.
* This trial also contributed 1,000 patients to a sub protocol measuring quality of life chaired by Prof. Lesley Fallowfield.
* Finally my group has developed a novel technique for delivering radiotherapy at the time of surgery which could save the NHS millions of pounds a year and opens up the way for women in the developing world to enjoy the option of retaining their breasts after surgery for early breast cancer. This technique, TARGIT is now in a multinational RCT in the UK, Europe, Australasia and the USA. I remain principle investigator.
* I established the first nurse counselling service at Kings College Hospital in 1981 and the first psychosocial oncology research team at the same time.
* I developed the first psychometric instrument for measuring quality of life in patients undergoing treatment for cancer (LASA).
* My group were also involved in developing the ethical models for randomised controlled trials and the development of informed consent procedures. This also included a consumer's advisory group. As Vice President of EUSOMA I was in part instrumental in building up EUROPA DONNA and worked closely with this organization as President of the third European Breast Cancer Conference 2002 in Barcelona that lead to the Statement of Barcelona on behalf of EUSOMA, EORTC and EUROPA DONNA.
* My group was the first to show the survival advantage of adjuvant tamoxifen, which has contributed to the 30% fall in breast cancer mortality over the last 15 years.
* As a spin off from these trials we were also the first to note the potential of tamoxifen to prevent breast cancer.
* Most recently I have put together the biggest International cancer trials group in history (ATAC), which in record time demonstrated the superiority of Anastrozole to tamoxifen. Anastrozole was endorsed by NICE as the preferred treatment for hormone responsive postmenopausal women with breast cancer in June 2006.
* Alongside this trial of over 9,000 patients we have a subcommittee responsible for collecting and storing archival material for translational research that will relate the response of the aromatase inhibitors to various phenotypes of breast cancer based on steroid and growth factor receptors.
* This trial also contributed 1,000 patients to a sub protocol measuring quality of life chaired by Prof. Lesley Fallowfield.
* Finally my group has developed a novel technique for delivering radiotherapy at the time of surgery which could save the NHS millions of pounds a year and opens up the way for women in the developing world to enjoy the option of retaining their breasts after surgery for early breast cancer. This technique, TARGIT is now in a multinational RCT in the UK, Europe, Australasia and the USA. I remain principle investigator.
